SQI Diagnostics to Submit Array-Based Assays to FDA for 2008 Launch | GenomeWeb
This story has been updated from a previous version, which incorrectly stated that SQI had signed an agreement with Bio-Rad. This was an error caused by an editing oversight.  
SQI Diagnostics, a Toronto-based automated medical systems developer, plans to submit array-based assays for rheumatoid arthritis and thrombosis to the US Food and Drug Administration in 2008 for a possible market launch that year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.